Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $9.20.

PYXS has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th. Royal Bank of Canada reiterated an “outperform” rating and set a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th.

Institutional Trading of Pyxis Oncology

Large investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in Pyxis Oncology by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after acquiring an additional 57,016 shares during the last quarter. Barclays PLC grew its stake in shares of Pyxis Oncology by 275.0% during the third quarter. Barclays PLC now owns 64,089 shares of the company’s stock valued at $235,000 after purchasing an additional 46,997 shares during the last quarter. State Street Corp grew its stake in shares of Pyxis Oncology by 28.0% during the third quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after purchasing an additional 208,344 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Pyxis Oncology by 88.1% in the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company’s stock valued at $468,000 after purchasing an additional 140,498 shares in the last quarter. Finally, Jane Street Group LLC raised its position in Pyxis Oncology by 40.8% in the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after purchasing an additional 14,349 shares during the last quarter. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Price Performance

Shares of PYXS stock opened at $1.06 on Thursday. The stock has a market cap of $65.29 million, a P/E ratio of -1.03 and a beta of 1.17. The stock has a fifty day moving average price of $1.09 and a 200 day moving average price of $1.93. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. The business had revenue of $16.15 million during the quarter. Equities research analysts anticipate that Pyxis Oncology will post -1.04 EPS for the current year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.